The combination of anti‐PD‐L1 immunotherapy plus VEGFR/CDK4/6 targeting agents is well tolerated and active in patients with advanced NSCLC, even in those whose tumors progressed on prior checkpoint blockade. This evidence concerns the gene KDR and non-small cell lung carcinoma.